Zion Market Research has published a new report titled “Viral Clearance Market by Method (Viral Removal (Chromatography, Precipitation, and Nanofiltration) and Viral Inactivation (Low pH, Solvent Detergent Method, Pasteurization, and Other Viral Inactivation Methods)), by Application (Blood and Blood Products, Recombinant Proteins, Vaccines, and Other Applications), and by End-User (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, CROs, and Other End-Users): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017–2024”. According to the report, the global viral clearance market was valued at approximately USD 230 million in 2017 and is expected to generate revenue of around USD 900 million by 2024, growing at a CAGR of around 21.41% between 2018 and 2024.
Biological products are prone to contamination with bacteria, fungi, and viruses. The source of contamination might be raw materials, improper culture handling, etc. Viral clearance is an important process during the downstream purification of therapeutic biologics, blood, and tissue-derived products. Viruses are either removed or inactivated. To produce microbiologically safe products, viral clearance plays a crucial role.
Get PDF Sample Copy of this Report to understand the structure of the complete report @ https://www.zionmarketresearch.com/sample/viral-clearance-market/news
Recombinant proteins have high potency and lesser side effects. They mimic naturally occurring proteins and, hence, are widely used worldwide. Thus, the growth is observed in the biopharmaceutical research and development field. Advances and investments made in the biotechnology and pharmaceutical industries drive the viral clearance market. Additionally, favorable research funding and government grants for product development contribute notably toward this market’s growth. The need for virus clearance in cell culture to avoid contamination, high burden of chronic disorders, and increasing aging population are also likely to contribute toward the viral clearance market. The high cost of technology and the time-consuming process of drug development might hamper this market’s growth. Growing demand for contract research organizations for pharmaceutical outsourcing along with potential emerging markets are likely to present lucrative opportunities for the viral clearance market in the upcoming years.
The viral clearance market is divided based on viral clearance method, application, and end-user. The viral clearance method segment is categorized into viral removal and viral inactivation. Viral removal segment is sub-segmented into chromatography, precipitation, and nanofiltration based on virus removal technique. The viral inactivation segment is sub-segmented into low pH, solvent detergent method, pasteurization, and other viral inactivation methods. In the viral removal segment, nanofiltration held the largest market share in 2017. Chromatographic viral removal segment is expected to grow at the fastest CAGR. By application, the viral clearance market is segmented into blood and blood products, recombinant proteins, vaccines, and other applications. The other applications include stem cell products, cellular and gene therapy products, tissue and tissue products etc. The recombinant proteins application segment dominated the market in 2017, owing to increased production and use of biosimilars and other therapeutic proteins for treating life-threatening diseases, such as cancer, diabetes, etc., globally. By end-user, this market includes pharmaceutical and biotechnology companies, academic research institutes, contract research organizations (CROs), and other end-users. The pharmaceutical and biotechnology companies segment dominated the viral clearance market in 2017 in terms of revenue share and is projected to lead during the forecast time period.
By region, the global viral clearance market is segmented into North America, Asia Pacific, the Middle East, and Africa, Europe, and Latin America. North America held the largest revenue share of about 42% in 2017 and is expected to maintain its position during the forecast time period. Factors promoting this regional market’s growth are growing biopharmaceutical research, favorable government funding, and huge research investments made by biopharmaceutical companies. High acceptance of biopharmaceutical products and increased spending on recombinant protein research are factors promoting this market’s growth in the European region. The Asia Pacific viral clearance market is growing rapidly, due to a large number of contract research organizations (CROs) in India and China, growth in generics and pharmaceutical manufacturing, and development in India, Malaysia, and Singapore. The Middle East and Africa market are likely to observe considerable growth in the upcoming years. Latin America is expected to witness moderate growth over the forecast time period.
Some key players operating in the viral clearance market include Merck KGaA, Wuxi Biologics (Cayman), Charles River Laboratories International Inc., Kedrion, Texcell Inc., Vironova Biosafety, Clean Cells, BSL BIOSERVICE Scientific Laboratories Munich GmbH, and ViruSure GmbH, among others.
This report segments the global viral clearance market as follows:
Global Viral Clearance Market: By Method
Global Viral Clearance Market: By Application
Global Viral Clearance Market: By End-User
Global Viral Clearance Market: By Region
You can Buy This Report from Here @ https://www.zionmarketresearch.com/buynow/su/viral-clearance-market/news